Dupilumab in patients with diffuse type 2 CRSwNP had beneficial changes in nasal passage microbiota but did not alter gastrointestinal microbiota.

Chronic rhinosinusitis with nasal polyps increases the likelihood of developing coexisting conditions, such as asthma, ...

A survey of ENT clinicians reveals variability in managing chronic rhinosinusitis with nasal polyps, including steroid ...

A study published in July 2025 issue of Journal of Allergy and Clinical Immunology Global highlighted persistent challenges ...

This new study explored how expression of SERPINB10 may be related to postoperative recurrence of and inflammation related to chronic rhinosinusitis with nasal polyps (CRSwNP).

Dupilumab improved nasal polyp outcomes and asthma symptoms more than omalizumab in patients with CRSwNP and asthma, according to the head-to-head EVEREST phase 4 trial.

Expanded approval of Dupixent to include as add-on treatment of patients 12 to 17 with inadequately controlled rhinosinusitis with polyps.

Dupixent has received regulatory approvals in more than 60 countries in one or more indications including certain patients with atopic dermatitis, asthma, CRSwNP, eosinophilic esophagitis, prurigo ...

Patients with CRSwNP have elevated levels of thymic stromal lymphopoietin (TSLP), Han said, which is a key driver of inflammation. Tezepelumab (Tezspire; Amgen, AstraZeneca) has been used to block ...

"China’s NMPA approves GSK’s Nucala for CRSwNP treatment" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand.

New late-breaking data at EAACI showed Dupixent outperformed Xolair across all primary and secondary efficacy endpoints of CRSwNP and in all asthma-related endpoints Dupixent also outperformed ...

UK-based pharmaceutical company GSK has reported positive outcomes from two Phase III trials of depemokimab for treating chronic rhinosinusitis with nasal polyps (CRSwNP) in adults.